{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:21:05Z","timestamp":1787181665319,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1054,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["GR-2013-02355028"],"award-info":[{"award-number":["GR-2013-02355028"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2015XSZ9A2"],"award-info":[{"award-number":["2015XSZ9A2"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017YZF7MA"],"award-info":[{"award-number":["2017YZF7MA"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13311-020-00893-8","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T17:03:23Z","timestamp":1595005403000},"page":"2004-2014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG\/Rij Rat Model of Absence Epilepsy"],"prefix":"10.1016","volume":"17","author":[{"given":"Antonio","family":"Leo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tallarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia M.","family":"Gallo Cantafio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Constanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-8123","authenticated-orcid":false,"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Citraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-020-00893-8_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tins.2013.11.002","article-title":"Inflammatory pathways of seizure disorders","volume":"37","author":"Marchi","year":"2014","journal-title":"Trends Neurosci"},{"key":"10.1007\/s13311-020-00893-8_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.13784","article-title":"Innate and adaptive immunity in human epilepsies","volume":"58","author":"Bauer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-020-00893-8_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tins.2012.11.008","article-title":"Glia and epilepsy: Excitability and inflammation","volume":"36","author":"Devinsky","year":"2013","journal-title":"Trends Neurosci"},{"key":"10.1007\/s13311-020-00893-8_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2018.08.020","article-title":"Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy","volume":"837","author":"Paudel","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-020-00893-8_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/epi.13786","article-title":"Neurobehavioral comorbidities of epilepsy: Role of inflammation","volume":"58","author":"Mazarati","year":"2017","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-020-00893-8_bib6","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.2174\/1381612823666170926113754","article-title":"Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation","volume":"23","author":"Terrone","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-020-00893-8_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/nan.12444","article-title":"Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies","volume":"44","author":"van Vliet","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1007\/s13311-020-00893-8_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eplepsyres.2011.03.004","article-title":"The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy","volume":"95","author":"Lehtim\u00e4ki","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-020-00893-8_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuropharm.2014.10.027","article-title":"Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability","volume":"96","author":"Vezzani","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-020-00893-8_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.13712","article-title":"Inflammation in psychiatric disorders: What comes first?","volume":"1437","author":"Bauer","year":"2019","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1007\/s13311-020-00893-8_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mp.2016.167","article-title":"Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions","volume":"23","author":"Kappelmann","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1007\/s13311-020-00893-8_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/epi.13766","article-title":"Psychiatric and behavioral comorbidities in epilepsy: A critical reappraisal","volume":"58","author":"Berg","year":"2017","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-020-00893-8_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of epilepsy: Current concepts and future perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-020-00893-8_bib14","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1523\/JNEUROSCI.2830-13.2014","article-title":"Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain","volume":"34","author":"Campbell","year":"2014","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-020-00893-8_bib15","first-page":"1218","article-title":"The role of interleukin-6 signaling in nervous tissue","volume":"2016","author":"Rothaug","year":"1863","journal-title":"Biochimica et Biophysica Acta - Molecular Cell Research"},{"key":"10.1007\/s13311-020-00893-8_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ynstr.2016.03.003","article-title":"Integrating Interleukin-6 into depression diagnosis and treatment","volume":"4","author":"Hodes","year":"2016","journal-title":"Neurobiology of Stress"},{"key":"10.1007\/s13311-020-00893-8_bib17","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.7150\/ijbs.4679","article-title":"Interleukin-6, a major cytokine in the central nervous system","volume":"8","author":"Erta","year":"2012","journal-title":"International Journal of Biological Sciences"},{"key":"10.1007\/s13311-020-00893-8_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2015.01.009","article-title":"IL-1\u03b2, IL-6 and IL1Ra levels in temporal lobe epilepsy","volume":"26","author":"Uludag","year":"2015","journal-title":"Seizure"},{"key":"10.1007\/s13311-020-00893-8_bib19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00415-009-5021-x","article-title":"Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy","volume":"256","author":"Liimatainen","year":"2009","journal-title":"J Neurol"},{"key":"10.1007\/s13311-020-00893-8_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0920-1211(00)00140-6","article-title":"Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures","volume":"41","author":"Peltola","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-020-00893-8_bib21","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1046\/j.1460-9568.2000.00140.x","article-title":"Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus","volume":"12","author":"De Simoni","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-020-00893-8_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/jamapsychiatry.2014.1332","article-title":"Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life a population-based longitudinal study","volume":"71","author":"Khandaker","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1007\/s13311-020-00893-8_bib23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.neubiorev.2016.09.017","article-title":"Upholding WAG\/Rij rats as a model of absence epileptogenesis: Hidden mechanisms and a new theory on seizure development","volume":"71","author":"Russo","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1007\/s13311-020-00893-8_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jneumeth.2018.05.020","article-title":"Pharmacology of epileptogenesis and related comorbidities in the WAG\/Rij rat model of genetic absence epilepsy","volume":"310","author":"Russo","year":"2018","journal-title":"J Neurosci Methods"},{"key":"10.1007\/s13311-020-00893-8_bib25","doi-asserted-by":"crossref","first-page":"109652","DOI":"10.1016\/j.pnpbp.2019.109652","article-title":"Cognitive impairment in the WAG\/Rij rat absence model is secondary to absence seizures and depressive-like behavior","volume":"94","author":"Leo","year":"2019","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"10.1007\/s13311-020-00893-8_bib26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11062-012-9252-6","article-title":"Cytokines and absence seizures in a genetic rat model","volume":"43","author":"Van Luijtelaar","year":"2012","journal-title":"Neurophysiology"},{"key":"10.1007\/s13311-020-00893-8_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbi.2013.09.001","article-title":"Brain protein expression changes in WAG\/Rij rats, a genetic rat model of absence epilepsy after peripheral lipopolysaccharide treatment","volume":"35","author":"Gy\u00f6rffy","year":"2014","journal-title":"Brain Behav Immun"},{"key":"10.1007\/s13311-020-00893-8_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1528-1167.2010.02606.x","article-title":"Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA","volume":"51","author":"Auvin","year":"2010","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-020-00893-8_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0361-9230(01)00445-2","article-title":"Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide","volume":"54","author":"Turrin","year":"2001","journal-title":"Brain Res Bull"},{"key":"10.1007\/s13311-020-00893-8_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbi.2014.06.016","article-title":"Early molecular and behavioral response to lipopolysaccharide in the WAG\/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT\/mTOR pathways and neuroinflammatory cytokine release","volume":"42","author":"Russo","year":"2014","journal-title":"Brain Behav Immun"},{"key":"10.1007\/s13311-020-00893-8_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.brainresbull.2014.03.003","article-title":"Lipopolysaccharide induced increase in seizure activity in two animal models of absence epilepsy WAG\/Rij and GAERS rats and Long Evans rats","volume":"104","author":"Kov\u00e1cs","year":"2014","journal-title":"Brain Res Bull"},{"key":"10.1007\/s13311-020-00893-8_bib32","doi-asserted-by":"crossref","unstructured":"Kishimoto T, Kang S, Tanaka T. IL-6: A New Era for the Treatment of Autoimmune Inflammatory Diseases. In: Innovative Medicine. 2015, pp. 131\u2013147.","DOI":"10.1007\/978-4-431-55651-0_11"},{"key":"10.1007\/s13311-020-00893-8_bib33","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.25374","article-title":"Tocilizumab treatment for new onset refractory status epilepticus","volume":"84","author":"Jun","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-020-00893-8_bib34","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamaneurol.2013.143","article-title":"Successful treatment of anti-caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab","volume":"70","author":"Krogias","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-020-00893-8_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/157488706778250168","article-title":"Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases","volume":"1","author":"Ding","year":"2008","journal-title":"Rev Recent Clin Trials"},{"key":"10.1007\/s13311-020-00893-8_bib36","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I\/II clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-020-00893-8_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/epi.13629","article-title":"Perampanel effects in the WAG\/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior","volume":"58","author":"Citraro","year":"2017","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-020-00893-8_bib38","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s13311-017-0550-y","article-title":"Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG\/Rij Rat Absence Epilepsy Model","volume":"14","author":"Leo","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-020-00893-8_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s13311-014-0318-6","article-title":"Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats","volume":"12","author":"Citraro","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-020-00893-8_bib40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12035-019-01712-8","article-title":"Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG\/Rij Rats","volume":"57","author":"Citraro","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-020-00893-8_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuropharm.2012.09.019","article-title":"MTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy","volume":"69","author":"Russo","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-020-00893-8_bib42","doi-asserted-by":"crossref","unstructured":"Terrone G, Balosso S, Pauletti A, et al. Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology; 167. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107742.","DOI":"10.1016\/j.neuropharm.2019.107742"},{"key":"10.1007\/s13311-020-00893-8_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.02.004","article-title":"Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG\/Rij rats","volume":"113","author":"Citraro","year":"2015","journal-title":"Brain Res Bull"},{"key":"10.1007\/s13311-020-00893-8_bib44","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neuropharm.2008.11.003","article-title":"T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b] pyridazine derivatives structurally related to indomethacin","volume":"56","author":"Rimoli","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-020-00893-8_bib45","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/j.1528-1167.2009.02400.x","article-title":"Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy","volume":"51","author":"Russo","year":"2010","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-020-00893-8_bib46","doi-asserted-by":"crossref","unstructured":"Cantar\u00edn-Extremera V, Jim\u00e9nez-Legido M, Duat-Rodr\u00edguez A, et al. Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients. J Neuroimmunol; 340. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577142.","DOI":"10.1016\/j.jneuroim.2019.577142"},{"key":"10.1007\/s13311-020-00893-8_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuropharm.2014.10.023","article-title":"IL-6 regulation of synaptic function in the CNS","volume":"96","author":"Gruol","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-020-00893-8_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nbd.2011.05.015","article-title":"IL-1\u03b2 is induced in reactive astrocytes in the somatosensory cortex of rats with genetic absence epilepsy at the onset of spike-and-wave discharges, and contributes to their occurrence","volume":"44","author":"Akin","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-020-00893-8_bib49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5606\/ArchRheumatol.2018.6753","article-title":"Effects of tocilizumab therapy on serum interleukin-33 and interleukin-6 levels in patients with rheumatoid arthritis","volume":"33","author":"Choi","year":"2018","journal-title":"Arch Rheumatol"},{"key":"10.1007\/s13311-020-00893-8_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5114\/ceji.2019.87066","article-title":"Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab","volume":"44","author":"Vilaiyuk","year":"2019","journal-title":"Cent Eur J Immunol"},{"key":"10.1007\/s13311-020-00893-8_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/seiz.2001.0575","article-title":"Indicators of inflammation after recent tonic-clonic epileptic seizures correlate with plasma interleukin-6 levels","volume":"11","author":"Peltola","year":"2002","journal-title":"Seizure"},{"key":"10.1007\/s13311-020-00893-8_bib52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0404.2007.00882.x","article-title":"Increased plasma levels of cytokines after seizures in localization-related epilepsy","volume":"116","author":"Lehtim\u00e4ki","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-020-00893-8_bib53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.braindev.2005.03.007","article-title":"Cerebrospinal fluid interleukin-6 levels in patients with west syndrome","volume":"28","author":"Tekgul","year":"2006","journal-title":"Brain Dev"},{"key":"10.1007\/s13311-020-00893-8_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jneuroim.2004.01.024","article-title":"Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: The effect of seizure type and duration","volume":"152","author":"Lehtim\u00e4ki","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-020-00893-8_bib55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.neubiorev.2016.02.007","article-title":"Inflammatory mediators in human epilepsy: A systematic review and meta-analysis","volume":"63","author":"de Vries","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1007\/s13311-020-00893-8_bib56","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0306-4522(03)00593-1","article-title":"Spatiotemporal distribution of gp130 cytokines and their receptors after status epilepticus: Comparison with neuronal degeneration and microglial activation","volume":"122","author":"Rosell","year":"2003","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-020-00893-8_bib57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neulet.2015.04.046","article-title":"Wistar Audiogenic Rats (WAR) exhibit altered levels of cytokines and brain-derived neurotrophic factor following audiogenic seizures","volume":"597","author":"de Souza Bernardino","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-020-00893-8_bib58","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.pharep.2019.04.017","article-title":"Antiepileptogenic effects of Ethosuximide and Levetiracetam in WAG\/Rij rats are only temporary","volume":"71","author":"Leo","year":"2019","journal-title":"Pharmacol Reports"},{"key":"10.1007\/s13311-020-00893-8_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1528-1167.2009.02260.x","article-title":"Spike-wave discharges are necessary for the expression of behavioral depression-like symptoms","volume":"51","author":"Sarkisova","year":"2010","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-020-00893-8_bib60","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.pnpbp.2010.11.010","article-title":"The WAG\/Rij strain: A genetic animal model of absence epilepsy with comorbidity of depressiony","volume":"35","author":"Sarkisova","year":"2011","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"10.1007\/s13311-020-00893-8_bib61","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1528-1167.2011.03112.x","article-title":"Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model","volume":"52","author":"Russo","year":"2011","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-020-00893-8_bib62","doi-asserted-by":"crossref","unstructured":"Mula M. Epilepsy and Psychiatric Comorbidities: Drug Selection. Current Treatment Options in Neurology; 19. https:\/\/doi.org\/10.1007\/s11940-017-0483-0.","DOI":"10.1007\/s11940-017-0483-0"},{"key":"10.1007\/s13311-020-00893-8_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.05.001","article-title":"The expression of interleukin-6 and its receptor in various brain regions and their roles in exploratory behavior and stress responses","volume":"284","author":"Aniszewska","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-020-00893-8_bib64","doi-asserted-by":"crossref","unstructured":"Sukoff Rizzo SJ, Neal SJ, Hughes ZA, et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry; 2. https:\/\/doi.org\/10.1038\/tp.2012.120.","DOI":"10.1038\/tp.2012.120"},{"key":"10.1007\/s13311-020-00893-8_bib65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbr.2008.05.009","article-title":"IL-6 mediated alterations on immobile behavior of rats in the forced swim test via ERK1\/2 activation in specific brain regions","volume":"193","author":"Wu","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1007\/s13311-020-00893-8_bib66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/brbi.1999.0576","article-title":"Behavioral effects of infection with IL-6 adenovector","volume":"15","author":"Sakic","year":"2001","journal-title":"Brain Behav Immun"},{"key":"10.1007\/s13311-020-00893-8_bib67","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.nbd.2006.05.001","article-title":"IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors","volume":"23","author":"Chourbaji","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-020-00893-8_bib68","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1523\/JNEUROSCI.1537-11.2011","article-title":"Constant darkness induces IL-6-dependent depression-like behavior through the NF-\u03baB signaling pathway","volume":"31","author":"Monje","year":"2011","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-020-00893-8_bib69","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jad.2011.08.003","article-title":"Interleukin (IL)-6, tumour necrosis factor alpha (TNF-\u03b1) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression","volume":"139","author":"Liu","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1007\/s13311-020-00893-8_bib70","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with c-reactive protein, IL-1, and IL-6: A meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom Med"},{"key":"10.1007\/s13311-020-00893-8_bib71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A Meta-Analysis of Cytokines in Major Depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-020-00893-8_bib72","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.bbi.2012.06.001","article-title":"A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: Exploring the causes of heterogeneity","volume":"26","author":"Hiles","year":"2012","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1007\/s13311-020-00893-8_bib73","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbi.2014.05.006","article-title":"Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample","volume":"41","author":"Kern","year":"2014","journal-title":"Brain Behav Immun"},{"key":"10.1007\/s13311-020-00893-8_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons between Schizophrenia, Bipolar Disorder, and Depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1007\/s13311-020-00893-8_bib75","doi-asserted-by":"crossref","unstructured":"Adzic M, Brkic Z, Mitic M, et al. Therapeutic Strategies for Treatment of Inflammation-related Depression. Curr Neuropharmacol; 16. https:\/\/doi.org\/10.2174\/1570159x15666170828163048.","DOI":"10.2174\/1570159X15666170828163048"},{"key":"10.1007\/s13311-020-00893-8_bib76","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s10067-014-2609-z","article-title":"Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab","volume":"33","author":"Traki","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-020-00893-8_bib77","first-page":"87","article-title":"The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: A systematic literature review and interpretation","volume":"4","author":"Townes","year":"2012","journal-title":"Open Access Rheumatology: Research and Reviews"},{"key":"10.1007\/s13311-020-00893-8_bib78","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bbi.2017.06.014","article-title":"The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease","volume":"66","author":"Sun","year":"2017","journal-title":"Brain Behav Immun"},{"key":"10.1007\/s13311-020-00893-8_bib79","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.neuroscience.2006.02.023","article-title":"Facilitation of spike-wave discharge activity by lipopolysaccharides in Wistar Albino Glaxo\/Rijswijk rats","volume":"140","author":"Kov\u00e1cs","year":"2006","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-020-00893-8_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0165-5728(91)90110-S","article-title":"Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production","volume":"33","author":"Woodroofe","year":"1991","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-020-00893-8_bib81","doi-asserted-by":"crossref","unstructured":"Minogue AM, Barrett JP, Lynch MA. LPS-induced release of IL-6 from glia modulates production of IL-1\u03b2 in a JAK2-dependent manner. J Neuroinflammation; 9. https:\/\/doi.org\/10.1186\/1742-2094-9-126.","DOI":"10.1186\/1742-2094-9-126"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00893-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:53:21Z","timestamp":1761807201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1878747923012904"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00893-8","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG\/Rij Rat Model of Absence Epilepsy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00893-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}